nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—CYP3A5—prostate cancer	0.183	0.698	CbGaD
Nateglinide—CYP3A4—prostate cancer	0.0793	0.302	CbGaD
Nateglinide—ORM1—Abiraterone—prostate cancer	0.0617	0.131	CbGbCtD
Nateglinide—ABCC4—Conjugated Estrogens—prostate cancer	0.0331	0.0705	CbGbCtD
Nateglinide—ALB—Abiraterone—prostate cancer	0.026	0.0553	CbGbCtD
Nateglinide—CYP3A5—Flutamide—prostate cancer	0.0209	0.0444	CbGbCtD
Nateglinide—ALB—Estrone—prostate cancer	0.0188	0.04	CbGbCtD
Nateglinide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0187	0.0398	CbGbCtD
Nateglinide—CYP2C9—Bicalutamide—prostate cancer	0.0169	0.036	CbGbCtD
Nateglinide—CYP2C9—Nilutamide—prostate cancer	0.0169	0.036	CbGbCtD
Nateglinide—CYP2D6—Bicalutamide—prostate cancer	0.0154	0.0329	CbGbCtD
Nateglinide—CYP3A5—Cabazitaxel—prostate cancer	0.0154	0.0329	CbGbCtD
Nateglinide—CYP3A5—Estrone—prostate cancer	0.0151	0.0321	CbGbCtD
Nateglinide—SLC22A6—Conjugated Estrogens—prostate cancer	0.0144	0.0307	CbGbCtD
Nateglinide—CYP2D6—Abiraterone—prostate cancer	0.0128	0.0272	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.0115	0.0246	CbGbCtD
Nateglinide—CYP3A7—Estradiol—prostate cancer	0.0115	0.0246	CbGbCtD
Nateglinide—ALB—Estradiol—prostate cancer	0.0108	0.023	CbGbCtD
Nateglinide—CYP2C9—Estrone—prostate cancer	0.0101	0.0215	CbGbCtD
Nateglinide—CYP3A4—Bicalutamide—prostate cancer	0.00982	0.0209	CbGbCtD
Nateglinide—PTGS1—Etoposide—prostate cancer	0.00942	0.0201	CbGbCtD
Nateglinide—ALB—Prednisone—prostate cancer	0.00927	0.0197	CbGbCtD
Nateglinide—CYP3A4—Estramustine—prostate cancer	0.00913	0.0194	CbGbCtD
Nateglinide—CYP3A5—Estradiol—prostate cancer	0.00866	0.0185	CbGbCtD
Nateglinide—CYP3A4—Abiraterone—prostate cancer	0.00814	0.0173	CbGbCtD
Nateglinide—CYP3A4—Flutamide—prostate cancer	0.00814	0.0173	CbGbCtD
Nateglinide—CYP2C9—Capecitabine—prostate cancer	0.00767	0.0163	CbGbCtD
Nateglinide—CYP3A7—Docetaxel—prostate cancer	0.0069	0.0147	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.0069	0.0147	CbGbCtD
Nateglinide—CYP3A4—Cabazitaxel—prostate cancer	0.00602	0.0128	CbGbCtD
Nateglinide—CYP3A4—Estrone—prostate cancer	0.00588	0.0125	CbGbCtD
Nateglinide—CYP2C9—Estradiol—prostate cancer	0.00581	0.0124	CbGbCtD
Nateglinide—ABCC8—penis—prostate cancer	0.00567	0.146	CbGeAlD
Nateglinide—CYP3A5—Etoposide—prostate cancer	0.00566	0.012	CbGbCtD
Nateglinide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00524	0.0112	CbGbCtD
Nateglinide—CYP3A5—Docetaxel—prostate cancer	0.00518	0.011	CbGbCtD
Nateglinide—CYP3A4—Conjugated Estrogens—prostate cancer	0.00385	0.0082	CbGbCtD
Nateglinide—CYP3A4—Mitoxantrone—prostate cancer	0.0035	0.00745	CbGbCtD
Nateglinide—CYP3A4—Estradiol—prostate cancer	0.00338	0.00719	CbGbCtD
Nateglinide—CYP3A4—Prednisone—prostate cancer	0.0029	0.00619	CbGbCtD
Nateglinide—CYP2D6—Doxorubicin—prostate cancer	0.00237	0.00504	CbGbCtD
Nateglinide—CYP3A4—Etoposide—prostate cancer	0.00221	0.0047	CbGbCtD
Nateglinide—CYP3A4—Docetaxel—prostate cancer	0.00202	0.0043	CbGbCtD
Nateglinide—CYP2C9—urine—prostate cancer	0.00169	0.0433	CbGeAlD
Nateglinide—CYP3A4—Doxorubicin—prostate cancer	0.0015	0.0032	CbGbCtD
Nateglinide—UGT1A9—renal system—prostate cancer	0.00143	0.0368	CbGeAlD
Nateglinide—ABCC8—prostate gland—prostate cancer	0.00136	0.0348	CbGeAlD
Nateglinide—CYP3A4—urine—prostate cancer	0.00129	0.033	CbGeAlD
Nateglinide—CYP2D6—urine—prostate cancer	0.00127	0.0325	CbGeAlD
Nateglinide—SLC16A1—prostate gland—prostate cancer	0.00123	0.0317	CbGeAlD
Nateglinide—PPARG—Teniposide—Etoposide—prostate cancer	0.00122	1	CbGdCrCtD
Nateglinide—ABCC8—seminal vesicle—prostate cancer	0.00115	0.0294	CbGeAlD
Nateglinide—ORM1—prostate gland—prostate cancer	0.00111	0.0284	CbGeAlD
Nateglinide—PPARG—prostate gland—prostate cancer	0.00103	0.0266	CbGeAlD
Nateglinide—SLC15A1—epithelium—prostate cancer	0.000952	0.0244	CbGeAlD
Nateglinide—ABCC4—prostate gland—prostate cancer	0.000939	0.0241	CbGeAlD
Nateglinide—ABCC8—renal system—prostate cancer	0.000924	0.0237	CbGeAlD
Nateglinide—SLC16A1—epithelium—prostate cancer	0.000906	0.0233	CbGeAlD
Nateglinide—SLC15A1—renal system—prostate cancer	0.000883	0.0227	CbGeAlD
Nateglinide—SLC16A1—renal system—prostate cancer	0.00084	0.0216	CbGeAlD
Nateglinide—SLC15A2—prostate gland—prostate cancer	0.00081	0.0208	CbGeAlD
Nateglinide—PPARG—epithelium—prostate cancer	0.00076	0.0195	CbGeAlD
Nateglinide—PPARG—renal system—prostate cancer	0.000705	0.0181	CbGeAlD
Nateglinide—PPARG—urethra—prostate cancer	0.000693	0.0178	CbGeAlD
Nateglinide—SLC15A2—seminal vesicle—prostate cancer	0.000685	0.0176	CbGeAlD
Nateglinide—ABCC4—renal system—prostate cancer	0.00064	0.0164	CbGeAlD
Nateglinide—CYP3A5—prostate gland—prostate cancer	0.000616	0.0158	CbGeAlD
Nateglinide—ABCC8—testis—prostate cancer	0.000597	0.0153	CbGeAlD
Nateglinide—ORM1—bone marrow—prostate cancer	0.00057	0.0146	CbGeAlD
Nateglinide—PTGS1—prostate gland—prostate cancer	0.000553	0.0142	CbGeAlD
Nateglinide—SLC15A2—renal system—prostate cancer	0.000552	0.0142	CbGeAlD
Nateglinide—SLC16A1—testis—prostate cancer	0.000543	0.0139	CbGeAlD
Nateglinide—SLC15A2—urethra—prostate cancer	0.000542	0.0139	CbGeAlD
Nateglinide—PPARG—bone marrow—prostate cancer	0.000533	0.0137	CbGeAlD
Nateglinide—ABCC4—bone marrow—prostate cancer	0.000484	0.0124	CbGeAlD
Nateglinide—KCNJ11—lymph node—prostate cancer	0.00047	0.0121	CbGeAlD
Nateglinide—PTGS1—seminal vesicle—prostate cancer	0.000468	0.012	CbGeAlD
Nateglinide—PPARG—testis—prostate cancer	0.000456	0.0117	CbGeAlD
Nateglinide—ALB—testis—prostate cancer	0.000428	0.011	CbGeAlD
Nateglinide—CYP3A5—renal system—prostate cancer	0.00042	0.0108	CbGeAlD
Nateglinide—ABCC4—testis—prostate cancer	0.000414	0.0106	CbGeAlD
Nateglinide—PTGS1—epithelium—prostate cancer	0.000406	0.0104	CbGeAlD
Nateglinide—SLC16A1—lymph node—prostate cancer	0.000394	0.0101	CbGeAlD
Nateglinide—PTGS1—renal system—prostate cancer	0.000377	0.00968	CbGeAlD
Nateglinide—L-Phenylalanine—TH—prostate cancer	0.00037	0.118	CrCbGaD
Nateglinide—SLC15A2—testis—prostate cancer	0.000357	0.00916	CbGeAlD
Nateglinide—ORM1—lymph node—prostate cancer	0.000353	0.00908	CbGeAlD
Nateglinide—PPARG—lymph node—prostate cancer	0.00033	0.00848	CbGeAlD
Nateglinide—CYP3A4—renal system—prostate cancer	0.000315	0.00809	CbGeAlD
Nateglinide—ALB—lymph node—prostate cancer	0.00031	0.00796	CbGeAlD
Nateglinide—CYP2D6—renal system—prostate cancer	0.00031	0.00796	CbGeAlD
Nateglinide—Spirapril—ACE—prostate cancer	0.000303	0.0969	CrCbGaD
Nateglinide—ABCC4—lymph node—prostate cancer	0.0003	0.0077	CbGeAlD
Nateglinide—Lisinopril—ACE—prostate cancer	0.00027	0.0864	CrCbGaD
Nateglinide—Cilazapril—ACE—prostate cancer	0.00027	0.0864	CrCbGaD
Nateglinide—Ramipril—ACE—prostate cancer	0.000262	0.0836	CrCbGaD
Nateglinide—Trandolapril—ACE—prostate cancer	0.000262	0.0836	CrCbGaD
Nateglinide—SLC15A2—lymph node—prostate cancer	0.000259	0.00664	CbGeAlD
Nateglinide—PTGS1—testis—prostate cancer	0.000244	0.00626	CbGeAlD
Nateglinide—Amphetamine—SLC22A3—prostate cancer	0.000236	0.0754	CrCbGaD
Nateglinide—Methamphetamine—SLC22A3—prostate cancer	0.000219	0.0699	CrCbGaD
Nateglinide—Diarrhoea—Bicalutamide—prostate cancer	0.000213	0.00202	CcSEcCtD
Nateglinide—Arthropathy—Doxorubicin—prostate cancer	0.000213	0.00201	CcSEcCtD
Nateglinide—Injury—Prednisone—prostate cancer	0.000211	0.002	CcSEcCtD
Nateglinide—Malnutrition—Estradiol—prostate cancer	0.00021	0.00199	CcSEcCtD
Nateglinide—Hyperhidrosis—Goserelin—prostate cancer	0.000209	0.00198	CcSEcCtD
Nateglinide—Urticaria—Ethinyl Estradiol—prostate cancer	0.000209	0.00198	CcSEcCtD
Nateglinide—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000208	0.00197	CcSEcCtD
Nateglinide—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.000208	0.00196	CcSEcCtD
Nateglinide—Increased appetite—Prednisone—prostate cancer	0.000207	0.00196	CcSEcCtD
Nateglinide—Dizziness—Bicalutamide—prostate cancer	0.000206	0.00195	CcSEcCtD
Nateglinide—Neuropathy peripheral—Etoposide—prostate cancer	0.000205	0.00194	CcSEcCtD
Nateglinide—Back pain—Estradiol—prostate cancer	0.000204	0.00193	CcSEcCtD
Nateglinide—Jaundice—Etoposide—prostate cancer	0.000203	0.00193	CcSEcCtD
Nateglinide—CYP2D6—testis—prostate cancer	0.0002	0.00514	CbGeAlD
Nateglinide—Enalapril—ACE—prostate cancer	0.000198	0.0634	CrCbGaD
Nateglinide—Vomiting—Bicalutamide—prostate cancer	0.000198	0.00187	CcSEcCtD
Nateglinide—Hepatobiliary disease—Etoposide—prostate cancer	0.000197	0.00187	CcSEcCtD
Nateglinide—Tremor—Estradiol—prostate cancer	0.000197	0.00187	CcSEcCtD
Nateglinide—Rash—Bicalutamide—prostate cancer	0.000196	0.00186	CcSEcCtD
Nateglinide—Dermatitis—Bicalutamide—prostate cancer	0.000196	0.00186	CcSEcCtD
Nateglinide—Bortezomib—CYP2C19—prostate cancer	0.000195	0.0623	CrCbGaD
Nateglinide—Osteoarthritis—Prednisone—prostate cancer	0.000194	0.00184	CcSEcCtD
Nateglinide—Bortezomib—CYP1A1—prostate cancer	0.000194	0.062	CrCbGaD
Nateglinide—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000194	0.00184	CcSEcCtD
Nateglinide—Dyspepsia—Goserelin—prostate cancer	0.000191	0.0018	CcSEcCtD
Nateglinide—Back pain—Mitoxantrone—prostate cancer	0.00019	0.00179	CcSEcCtD
Nateglinide—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000189	0.00179	CcSEcCtD
Nateglinide—Asthenia—Ethinyl Estradiol—prostate cancer	0.000189	0.00179	CcSEcCtD
Nateglinide—Influenza—Capecitabine—prostate cancer	0.000188	0.00178	CcSEcCtD
Nateglinide—Fatigue—Goserelin—prostate cancer	0.000187	0.00177	CcSEcCtD
Nateglinide—Pruritus—Ethinyl Estradiol—prostate cancer	0.000186	0.00176	CcSEcCtD
Nateglinide—Palpitations—Estradiol—prostate cancer	0.000186	0.00176	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000185	0.00175	CcSEcCtD
Nateglinide—Fatigue—Conjugated Estrogens—prostate cancer	0.000185	0.00175	CcSEcCtD
Nateglinide—Nausea—Bicalutamide—prostate cancer	0.000185	0.00175	CcSEcCtD
Nateglinide—Cough—Estradiol—prostate cancer	0.000184	0.00174	CcSEcCtD
Nateglinide—Sweating increased—Capecitabine—prostate cancer	0.000184	0.00174	CcSEcCtD
Nateglinide—Bronchitis—Capecitabine—prostate cancer	0.000181	0.00171	CcSEcCtD
Nateglinide—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00018	0.0017	CcSEcCtD
Nateglinide—Gastrointestinal pain—Goserelin—prostate cancer	0.000177	0.00168	CcSEcCtD
Nateglinide—Erythema multiforme—Etoposide—prostate cancer	0.000177	0.00168	CcSEcCtD
Nateglinide—PTGS1—lymph node—prostate cancer	0.000177	0.00454	CbGeAlD
Nateglinide—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000176	0.00166	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Capecitabine—prostate cancer	0.000175	0.00166	CcSEcCtD
Nateglinide—Dizziness—Ethinyl Estradiol—prostate cancer	0.000174	0.00165	CcSEcCtD
Nateglinide—Urticaria—Goserelin—prostate cancer	0.000172	0.00163	CcSEcCtD
Nateglinide—Abdominal pain—Goserelin—prostate cancer	0.000171	0.00162	CcSEcCtD
Nateglinide—Cough—Mitoxantrone—prostate cancer	0.000171	0.00162	CcSEcCtD
Nateglinide—Urticaria—Conjugated Estrogens—prostate cancer	0.000171	0.00161	CcSEcCtD
Nateglinide—Neuropathy peripheral—Docetaxel—prostate cancer	0.00017	0.00161	CcSEcCtD
Nateglinide—Abdominal pain—Conjugated Estrogens—prostate cancer	0.00017	0.00161	CcSEcCtD
Nateglinide—Immune system disorder—Etoposide—prostate cancer	0.000169	0.0016	CcSEcCtD
Nateglinide—Jaundice—Docetaxel—prostate cancer	0.000169	0.0016	CcSEcCtD
Nateglinide—Vomiting—Ethinyl Estradiol—prostate cancer	0.000167	0.00158	CcSEcCtD
Nateglinide—Hyperhidrosis—Estradiol—prostate cancer	0.000166	0.00157	CcSEcCtD
Nateglinide—Rash—Ethinyl Estradiol—prostate cancer	0.000166	0.00157	CcSEcCtD
Nateglinide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000166	0.00157	CcSEcCtD
Nateglinide—Neuropathy peripheral—Capecitabine—prostate cancer	0.000165	0.00156	CcSEcCtD
Nateglinide—Hepatobiliary disease—Docetaxel—prostate cancer	0.000164	0.00155	CcSEcCtD
Nateglinide—Jaundice—Capecitabine—prostate cancer	0.000164	0.00155	CcSEcCtD
Nateglinide—Sweating increased—Prednisone—prostate cancer	0.000163	0.00155	CcSEcCtD
Nateglinide—Increased appetite—Epirubicin—prostate cancer	0.000162	0.00153	CcSEcCtD
Nateglinide—Hypersensitivity—Goserelin—prostate cancer	0.00016	0.00151	CcSEcCtD
Nateglinide—Hepatobiliary disease—Capecitabine—prostate cancer	0.000159	0.0015	CcSEcCtD
Nateglinide—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000158	0.0015	CcSEcCtD
Nateglinide—Back pain—Etoposide—prostate cancer	0.000158	0.00149	CcSEcCtD
Nateglinide—Nausea—Ethinyl Estradiol—prostate cancer	0.000156	0.00148	CcSEcCtD
Nateglinide—Hypoglycaemia—Epirubicin—prostate cancer	0.000156	0.00147	CcSEcCtD
Nateglinide—Asthenia—Goserelin—prostate cancer	0.000155	0.00147	CcSEcCtD
Nateglinide—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000155	0.00146	CcSEcCtD
Nateglinide—Asthenia—Conjugated Estrogens—prostate cancer	0.000154	0.00146	CcSEcCtD
Nateglinide—Oedema peripheral—Docetaxel—prostate cancer	0.000153	0.00145	CcSEcCtD
Nateglinide—Pruritus—Goserelin—prostate cancer	0.000153	0.00145	CcSEcCtD
Nateglinide—Pruritus—Conjugated Estrogens—prostate cancer	0.000152	0.00144	CcSEcCtD
Nateglinide—Osteoarthritis—Epirubicin—prostate cancer	0.000152	0.00144	CcSEcCtD
Nateglinide—Dyspepsia—Estradiol—prostate cancer	0.000151	0.00143	CcSEcCtD
Nateglinide—Increased appetite—Doxorubicin—prostate cancer	0.00015	0.00141	CcSEcCtD
Nateglinide—Oedema peripheral—Capecitabine—prostate cancer	0.000149	0.00141	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Estradiol—prostate cancer	0.000148	0.0014	CcSEcCtD
Nateglinide—Diarrhoea—Goserelin—prostate cancer	0.000148	0.0014	CcSEcCtD
Nateglinide—Fatigue—Estradiol—prostate cancer	0.000148	0.0014	CcSEcCtD
Nateglinide—Erythema multiforme—Docetaxel—prostate cancer	0.000147	0.00139	CcSEcCtD
Nateglinide—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000147	0.00139	CcSEcCtD
Nateglinide—Neuropathy peripheral—Prednisone—prostate cancer	0.000147	0.00139	CcSEcCtD
Nateglinide—Hypoglycaemia—Doxorubicin—prostate cancer	0.000144	0.00136	CcSEcCtD
Nateglinide—Dizziness—Goserelin—prostate cancer	0.000143	0.00136	CcSEcCtD
Nateglinide—Erythema multiforme—Capecitabine—prostate cancer	0.000143	0.00135	CcSEcCtD
Nateglinide—Cough—Etoposide—prostate cancer	0.000142	0.00135	CcSEcCtD
Nateglinide—Dizziness—Conjugated Estrogens—prostate cancer	0.000142	0.00134	CcSEcCtD
Nateglinide—Dyspepsia—Mitoxantrone—prostate cancer	0.000141	0.00133	CcSEcCtD
Nateglinide—Immune system disorder—Docetaxel—prostate cancer	0.000141	0.00133	CcSEcCtD
Nateglinide—Osteoarthritis—Doxorubicin—prostate cancer	0.000141	0.00133	CcSEcCtD
Nateglinide—Gastrointestinal pain—Estradiol—prostate cancer	0.00014	0.00133	CcSEcCtD
Nateglinide—Fatigue—Mitoxantrone—prostate cancer	0.000138	0.00131	CcSEcCtD
Nateglinide—Vomiting—Goserelin—prostate cancer	0.000138	0.0013	CcSEcCtD
Nateglinide—Rash—Goserelin—prostate cancer	0.000137	0.00129	CcSEcCtD
Nateglinide—Dermatitis—Goserelin—prostate cancer	0.000137	0.00129	CcSEcCtD
Nateglinide—Vomiting—Conjugated Estrogens—prostate cancer	0.000136	0.00129	CcSEcCtD
Nateglinide—Urticaria—Estradiol—prostate cancer	0.000136	0.00129	CcSEcCtD
Nateglinide—Immune system disorder—Capecitabine—prostate cancer	0.000136	0.00129	CcSEcCtD
Nateglinide—Abdominal pain—Estradiol—prostate cancer	0.000136	0.00128	CcSEcCtD
Nateglinide—Malnutrition—Docetaxel—prostate cancer	0.000136	0.00128	CcSEcCtD
Nateglinide—Rash—Conjugated Estrogens—prostate cancer	0.000135	0.00128	CcSEcCtD
Nateglinide—Dermatitis—Conjugated Estrogens—prostate cancer	0.000135	0.00128	CcSEcCtD
Nateglinide—Amphetamine—CYP2A6—prostate cancer	0.000132	0.0423	CrCbGaD
Nateglinide—Malnutrition—Capecitabine—prostate cancer	0.000131	0.00124	CcSEcCtD
Nateglinide—Influenza—Epirubicin—prostate cancer	0.000131	0.00124	CcSEcCtD
Nateglinide—Back pain—Docetaxel—prostate cancer	0.000131	0.00124	CcSEcCtD
Nateglinide—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000131	0.00124	CcSEcCtD
Nateglinide—Nausea—Goserelin—prostate cancer	0.000129	0.00122	CcSEcCtD
Nateglinide—Hyperhidrosis—Etoposide—prostate cancer	0.000129	0.00122	CcSEcCtD
Nateglinide—Nausea—Conjugated Estrogens—prostate cancer	0.000128	0.00121	CcSEcCtD
Nateglinide—Urticaria—Mitoxantrone—prostate cancer	0.000127	0.0012	CcSEcCtD
Nateglinide—Back pain—Capecitabine—prostate cancer	0.000127	0.0012	CcSEcCtD
Nateglinide—Hypersensitivity—Estradiol—prostate cancer	0.000127	0.0012	CcSEcCtD
Nateglinide—Abdominal pain—Mitoxantrone—prostate cancer	0.000127	0.0012	CcSEcCtD
Nateglinide—Bronchitis—Epirubicin—prostate cancer	0.000126	0.00119	CcSEcCtD
Nateglinide—Bortezomib—CYP3A4—prostate cancer	0.000124	0.0396	CrCbGaD
Nateglinide—Asthenia—Estradiol—prostate cancer	0.000123	0.00117	CcSEcCtD
Nateglinide—Tremor—Capecitabine—prostate cancer	0.000123	0.00116	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000122	0.00115	CcSEcCtD
Nateglinide—Pruritus—Estradiol—prostate cancer	0.000122	0.00115	CcSEcCtD
Nateglinide—Influenza—Doxorubicin—prostate cancer	0.000121	0.00115	CcSEcCtD
Nateglinide—Immune system disorder—Prednisone—prostate cancer	0.000121	0.00115	CcSEcCtD
Nateglinide—Palpitations—Docetaxel—prostate cancer	0.00012	0.00113	CcSEcCtD
Nateglinide—Cough—Docetaxel—prostate cancer	0.000118	0.00112	CcSEcCtD
Nateglinide—Hypersensitivity—Mitoxantrone—prostate cancer	0.000118	0.00112	CcSEcCtD
Nateglinide—Diarrhoea—Estradiol—prostate cancer	0.000118	0.00111	CcSEcCtD
Nateglinide—Malnutrition—Prednisone—prostate cancer	0.000117	0.00111	CcSEcCtD
Nateglinide—Bronchitis—Doxorubicin—prostate cancer	0.000117	0.0011	CcSEcCtD
Nateglinide—Palpitations—Capecitabine—prostate cancer	0.000116	0.0011	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Etoposide—prostate cancer	0.000115	0.00109	CcSEcCtD
Nateglinide—Asthenia—Mitoxantrone—prostate cancer	0.000115	0.00109	CcSEcCtD
Nateglinide—Fatigue—Etoposide—prostate cancer	0.000115	0.00109	CcSEcCtD
Nateglinide—Neuropathy peripheral—Epirubicin—prostate cancer	0.000115	0.00109	CcSEcCtD
Nateglinide—Cough—Capecitabine—prostate cancer	0.000115	0.00108	CcSEcCtD
Nateglinide—Jaundice—Epirubicin—prostate cancer	0.000114	0.00108	CcSEcCtD
Nateglinide—Dizziness—Estradiol—prostate cancer	0.000114	0.00107	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000113	0.00107	CcSEcCtD
Nateglinide—Sweating—Epirubicin—prostate cancer	0.000112	0.00106	CcSEcCtD
Nateglinide—Hepatobiliary disease—Epirubicin—prostate cancer	0.000111	0.00105	CcSEcCtD
Nateglinide—Diarrhoea—Mitoxantrone—prostate cancer	0.00011	0.00104	CcSEcCtD
Nateglinide—Vomiting—Estradiol—prostate cancer	0.000109	0.00103	CcSEcCtD
Nateglinide—Gastrointestinal pain—Etoposide—prostate cancer	0.000109	0.00103	CcSEcCtD
Nateglinide—Rash—Estradiol—prostate cancer	0.000108	0.00102	CcSEcCtD
Nateglinide—Dermatitis—Estradiol—prostate cancer	0.000108	0.00102	CcSEcCtD
Nateglinide—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000106	0.001	CcSEcCtD
Nateglinide—Urticaria—Etoposide—prostate cancer	0.000106	0.001	CcSEcCtD
Nateglinide—Jaundice—Doxorubicin—prostate cancer	0.000106	0.000999	CcSEcCtD
Nateglinide—Abdominal pain—Etoposide—prostate cancer	0.000105	0.000996	CcSEcCtD
Nateglinide—Sweating—Doxorubicin—prostate cancer	0.000104	0.000982	CcSEcCtD
Nateglinide—Hyperhidrosis—Capecitabine—prostate cancer	0.000104	0.00098	CcSEcCtD
Nateglinide—Oedema peripheral—Epirubicin—prostate cancer	0.000103	0.000979	CcSEcCtD
Nateglinide—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000102	0.000969	CcSEcCtD
Nateglinide—Nausea—Estradiol—prostate cancer	0.000102	0.000965	CcSEcCtD
Nateglinide—Vomiting—Mitoxantrone—prostate cancer	0.000102	0.000963	CcSEcCtD
Nateglinide—Rash—Mitoxantrone—prostate cancer	0.000101	0.000955	CcSEcCtD
Nateglinide—Dermatitis—Mitoxantrone—prostate cancer	0.000101	0.000954	CcSEcCtD
Nateglinide—Erythema multiforme—Epirubicin—prostate cancer	9.93e-05	0.00094	CcSEcCtD
Nateglinide—Hypersensitivity—Etoposide—prostate cancer	9.81e-05	0.000928	CcSEcCtD
Nateglinide—Dyspepsia—Docetaxel—prostate cancer	9.74e-05	0.000922	CcSEcCtD
Nateglinide—Oedema peripheral—Doxorubicin—prostate cancer	9.58e-05	0.000906	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Docetaxel—prostate cancer	9.55e-05	0.000904	CcSEcCtD
Nateglinide—Asthenia—Etoposide—prostate cancer	9.55e-05	0.000904	CcSEcCtD
Nateglinide—Fatigue—Docetaxel—prostate cancer	9.54e-05	0.000903	CcSEcCtD
Nateglinide—Nausea—Mitoxantrone—prostate cancer	9.51e-05	0.0009	CcSEcCtD
Nateglinide—Immune system disorder—Epirubicin—prostate cancer	9.49e-05	0.000898	CcSEcCtD
Nateglinide—Dyspepsia—Capecitabine—prostate cancer	9.43e-05	0.000892	CcSEcCtD
Nateglinide—Pruritus—Etoposide—prostate cancer	9.42e-05	0.000891	CcSEcCtD
Nateglinide—Enalapril—CYP3A4—prostate cancer	9.32e-05	0.0298	CrCbGaD
Nateglinide—Gastrointestinal disorder—Capecitabine—prostate cancer	9.25e-05	0.000875	CcSEcCtD
Nateglinide—Fatigue—Capecitabine—prostate cancer	9.24e-05	0.000874	CcSEcCtD
Nateglinide—Hyperhidrosis—Prednisone—prostate cancer	9.23e-05	0.000873	CcSEcCtD
Nateglinide—Erythema multiforme—Doxorubicin—prostate cancer	9.19e-05	0.00087	CcSEcCtD
Nateglinide—Malnutrition—Epirubicin—prostate cancer	9.14e-05	0.000865	CcSEcCtD
Nateglinide—Diarrhoea—Etoposide—prostate cancer	9.11e-05	0.000862	CcSEcCtD
Nateglinide—Gastrointestinal pain—Docetaxel—prostate cancer	9.05e-05	0.000856	CcSEcCtD
Nateglinide—Back pain—Epirubicin—prostate cancer	8.85e-05	0.000837	CcSEcCtD
Nateglinide—Dizziness—Etoposide—prostate cancer	8.8e-05	0.000833	CcSEcCtD
Nateglinide—Immune system disorder—Doxorubicin—prostate cancer	8.78e-05	0.000831	CcSEcCtD
Nateglinide—Gastrointestinal pain—Capecitabine—prostate cancer	8.76e-05	0.000829	CcSEcCtD
Nateglinide—Abdominal pain—Docetaxel—prostate cancer	8.75e-05	0.000828	CcSEcCtD
Nateglinide—Urticaria—Capecitabine—prostate cancer	8.51e-05	0.000805	CcSEcCtD
Nateglinide—Abdominal pain—Capecitabine—prostate cancer	8.47e-05	0.000801	CcSEcCtD
Nateglinide—Vomiting—Etoposide—prostate cancer	8.47e-05	0.000801	CcSEcCtD
Nateglinide—Malnutrition—Doxorubicin—prostate cancer	8.46e-05	0.000801	CcSEcCtD
Nateglinide—Dyspepsia—Prednisone—prostate cancer	8.4e-05	0.000795	CcSEcCtD
Nateglinide—Rash—Etoposide—prostate cancer	8.4e-05	0.000794	CcSEcCtD
Nateglinide—Dermatitis—Etoposide—prostate cancer	8.39e-05	0.000794	CcSEcCtD
Nateglinide—Fatigue—Prednisone—prostate cancer	8.23e-05	0.000778	CcSEcCtD
Nateglinide—Back pain—Doxorubicin—prostate cancer	8.18e-05	0.000774	CcSEcCtD
Nateglinide—Hypersensitivity—Docetaxel—prostate cancer	8.15e-05	0.000771	CcSEcCtD
Nateglinide—Palpitations—Epirubicin—prostate cancer	8.08e-05	0.000765	CcSEcCtD
Nateglinide—Cough—Epirubicin—prostate cancer	7.98e-05	0.000755	CcSEcCtD
Nateglinide—Asthenia—Docetaxel—prostate cancer	7.94e-05	0.000751	CcSEcCtD
Nateglinide—Nausea—Etoposide—prostate cancer	7.91e-05	0.000748	CcSEcCtD
Nateglinide—Hypersensitivity—Capecitabine—prostate cancer	7.89e-05	0.000747	CcSEcCtD
Nateglinide—Pruritus—Docetaxel—prostate cancer	7.83e-05	0.000741	CcSEcCtD
Nateglinide—Gastrointestinal pain—Prednisone—prostate cancer	7.8e-05	0.000738	CcSEcCtD
Nateglinide—Asthenia—Capecitabine—prostate cancer	7.69e-05	0.000727	CcSEcCtD
Nateglinide—Urticaria—Prednisone—prostate cancer	7.58e-05	0.000717	CcSEcCtD
Nateglinide—Pruritus—Capecitabine—prostate cancer	7.58e-05	0.000717	CcSEcCtD
Nateglinide—Diarrhoea—Docetaxel—prostate cancer	7.57e-05	0.000716	CcSEcCtD
Nateglinide—Abdominal pain—Prednisone—prostate cancer	7.54e-05	0.000714	CcSEcCtD
Nateglinide—Palpitations—Doxorubicin—prostate cancer	7.48e-05	0.000707	CcSEcCtD
Nateglinide—Cough—Doxorubicin—prostate cancer	7.38e-05	0.000699	CcSEcCtD
Nateglinide—Diarrhoea—Capecitabine—prostate cancer	7.33e-05	0.000694	CcSEcCtD
Nateglinide—Dizziness—Docetaxel—prostate cancer	7.32e-05	0.000692	CcSEcCtD
Nateglinide—Hyperhidrosis—Epirubicin—prostate cancer	7.22e-05	0.000683	CcSEcCtD
Nateglinide—Dizziness—Capecitabine—prostate cancer	7.08e-05	0.00067	CcSEcCtD
Nateglinide—Vomiting—Docetaxel—prostate cancer	7.04e-05	0.000666	CcSEcCtD
Nateglinide—Hypersensitivity—Prednisone—prostate cancer	7.03e-05	0.000665	CcSEcCtD
Nateglinide—Rash—Docetaxel—prostate cancer	6.98e-05	0.00066	CcSEcCtD
Nateglinide—Dermatitis—Docetaxel—prostate cancer	6.97e-05	0.000659	CcSEcCtD
Nateglinide—Asthenia—Prednisone—prostate cancer	6.85e-05	0.000648	CcSEcCtD
Nateglinide—Vomiting—Capecitabine—prostate cancer	6.81e-05	0.000644	CcSEcCtD
Nateglinide—Rash—Capecitabine—prostate cancer	6.75e-05	0.000639	CcSEcCtD
Nateglinide—Pruritus—Prednisone—prostate cancer	6.75e-05	0.000639	CcSEcCtD
Nateglinide—Dermatitis—Capecitabine—prostate cancer	6.75e-05	0.000638	CcSEcCtD
Nateglinide—Hyperhidrosis—Doxorubicin—prostate cancer	6.68e-05	0.000632	CcSEcCtD
Nateglinide—Nausea—Docetaxel—prostate cancer	6.57e-05	0.000622	CcSEcCtD
Nateglinide—Dyspepsia—Epirubicin—prostate cancer	6.57e-05	0.000622	CcSEcCtD
Nateglinide—Diarrhoea—Prednisone—prostate cancer	6.53e-05	0.000618	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Epirubicin—prostate cancer	6.44e-05	0.00061	CcSEcCtD
Nateglinide—Fatigue—Epirubicin—prostate cancer	6.43e-05	0.000609	CcSEcCtD
Nateglinide—Nausea—Capecitabine—prostate cancer	6.36e-05	0.000602	CcSEcCtD
Nateglinide—Dizziness—Prednisone—prostate cancer	6.31e-05	0.000597	CcSEcCtD
Nateglinide—Gastrointestinal pain—Epirubicin—prostate cancer	6.1e-05	0.000577	CcSEcCtD
Nateglinide—Dyspepsia—Doxorubicin—prostate cancer	6.08e-05	0.000575	CcSEcCtD
Nateglinide—Vomiting—Prednisone—prostate cancer	6.07e-05	0.000574	CcSEcCtD
Nateglinide—Rash—Prednisone—prostate cancer	6.02e-05	0.000569	CcSEcCtD
Nateglinide—Dermatitis—Prednisone—prostate cancer	6.01e-05	0.000569	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.96e-05	0.000564	CcSEcCtD
Nateglinide—Fatigue—Doxorubicin—prostate cancer	5.95e-05	0.000563	CcSEcCtD
Nateglinide—Urticaria—Epirubicin—prostate cancer	5.93e-05	0.000561	CcSEcCtD
Nateglinide—Abdominal pain—Epirubicin—prostate cancer	5.9e-05	0.000558	CcSEcCtD
Nateglinide—Nausea—Prednisone—prostate cancer	5.67e-05	0.000536	CcSEcCtD
Nateglinide—Gastrointestinal pain—Doxorubicin—prostate cancer	5.65e-05	0.000534	CcSEcCtD
Nateglinide—Hypersensitivity—Epirubicin—prostate cancer	5.5e-05	0.00052	CcSEcCtD
Nateglinide—Urticaria—Doxorubicin—prostate cancer	5.49e-05	0.000519	CcSEcCtD
Nateglinide—Abdominal pain—Doxorubicin—prostate cancer	5.46e-05	0.000516	CcSEcCtD
Nateglinide—Asthenia—Epirubicin—prostate cancer	5.35e-05	0.000507	CcSEcCtD
Nateglinide—Pruritus—Epirubicin—prostate cancer	5.28e-05	0.0005	CcSEcCtD
Nateglinide—Diarrhoea—Epirubicin—prostate cancer	5.11e-05	0.000483	CcSEcCtD
Nateglinide—Hypersensitivity—Doxorubicin—prostate cancer	5.09e-05	0.000481	CcSEcCtD
Nateglinide—Asthenia—Doxorubicin—prostate cancer	4.95e-05	0.000469	CcSEcCtD
Nateglinide—Dizziness—Epirubicin—prostate cancer	4.94e-05	0.000467	CcSEcCtD
Nateglinide—Pruritus—Doxorubicin—prostate cancer	4.89e-05	0.000462	CcSEcCtD
Nateglinide—Vomiting—Epirubicin—prostate cancer	4.75e-05	0.000449	CcSEcCtD
Nateglinide—Diarrhoea—Doxorubicin—prostate cancer	4.73e-05	0.000447	CcSEcCtD
Nateglinide—Rash—Epirubicin—prostate cancer	4.71e-05	0.000445	CcSEcCtD
Nateglinide—Dermatitis—Epirubicin—prostate cancer	4.7e-05	0.000445	CcSEcCtD
Nateglinide—Dizziness—Doxorubicin—prostate cancer	4.57e-05	0.000432	CcSEcCtD
Nateglinide—Nausea—Epirubicin—prostate cancer	4.43e-05	0.000419	CcSEcCtD
Nateglinide—Vomiting—Doxorubicin—prostate cancer	4.39e-05	0.000415	CcSEcCtD
Nateglinide—Rash—Doxorubicin—prostate cancer	4.35e-05	0.000412	CcSEcCtD
Nateglinide—Dermatitis—Doxorubicin—prostate cancer	4.35e-05	0.000412	CcSEcCtD
Nateglinide—Nausea—Doxorubicin—prostate cancer	4.1e-05	0.000388	CcSEcCtD
Nateglinide—CYP2D6—Metabolism—CYP2A6—prostate cancer	2.68e-06	2.25e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.67e-06	2.24e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP3A4—prostate cancer	2.66e-06	2.24e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP2A6—prostate cancer	2.65e-06	2.23e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—COMT—prostate cancer	2.65e-06	2.23e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CAV1—prostate cancer	2.65e-06	2.23e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.64e-06	2.22e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.64e-06	2.22e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CB—prostate cancer	2.64e-06	2.22e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTP1—prostate cancer	2.64e-06	2.22e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTGS2—prostate cancer	2.62e-06	2.2e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP1B1—prostate cancer	2.61e-06	2.2e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CD—prostate cancer	2.6e-06	2.19e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—AKR1C3—prostate cancer	2.6e-06	2.19e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ITPR1—prostate cancer	2.6e-06	2.18e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PRKACB—prostate cancer	2.59e-06	2.18e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—AKR1C3—prostate cancer	2.58e-06	2.17e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PRKACB—prostate cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP17A1—prostate cancer	2.56e-06	2.16e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HSD3B1—prostate cancer	2.56e-06	2.15e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC22A3—prostate cancer	2.56e-06	2.15e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP17A1—prostate cancer	2.54e-06	2.14e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.53e-06	2.13e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GGT1—prostate cancer	2.53e-06	2.13e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.51e-06	2.11e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NCOA1—prostate cancer	2.49e-06	2.1e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CG—prostate cancer	2.49e-06	2.1e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—NOS3—prostate cancer	2.46e-06	2.07e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP19A1—prostate cancer	2.46e-06	2.07e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTA4—prostate cancer	2.46e-06	2.07e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.46e-06	2.07e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—TYMS—prostate cancer	2.45e-06	2.06e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NCOA2—prostate cancer	2.44e-06	2.05e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MYC—prostate cancer	2.44e-06	2.05e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTM1—prostate cancer	2.43e-06	2.04e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NCOA2—prostate cancer	2.42e-06	2.04e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—EP300—prostate cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CG—prostate cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTA2—prostate cancer	2.39e-06	2.01e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—LPL—prostate cancer	2.38e-06	2e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—RXRA—prostate cancer	2.37e-06	1.99e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.36e-06	1.99e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ABCG5—prostate cancer	2.36e-06	1.99e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—INS—prostate cancer	2.36e-06	1.98e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—SRC—prostate cancer	2.35e-06	1.98e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC5A5—prostate cancer	2.33e-06	1.96e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CREBBP—prostate cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTA1—prostate cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CYP1A1—prostate cancer	2.3e-06	1.93e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—VEGFA—prostate cancer	2.29e-06	1.92e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—INS—prostate cancer	2.29e-06	1.92e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—COMT—prostate cancer	2.28e-06	1.92e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTO1—prostate cancer	2.28e-06	1.92e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NAT2—prostate cancer	2.28e-06	1.92e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.28e-06	1.92e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTEN—prostate cancer	2.28e-06	1.92e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ERCC2—prostate cancer	2.28e-06	1.92e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP2E1—prostate cancer	2.28e-06	1.91e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTP1—prostate cancer	2.27e-06	1.91e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CB—prostate cancer	2.27e-06	1.91e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.26e-06	1.9e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NQO1—prostate cancer	2.25e-06	1.89e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTGS2—prostate cancer	2.25e-06	1.89e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PIK3CA—prostate cancer	2.25e-06	1.89e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CREBBP—prostate cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ITPR1—prostate cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NQO1—prostate cancer	2.23e-06	1.88e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—TH—prostate cancer	2.22e-06	1.87e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.2e-06	1.85e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—TH—prostate cancer	2.2e-06	1.85e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.19e-06	1.85e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CD—prostate cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LRP2—prostate cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PLCB2—prostate cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.18e-06	1.84e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PIK3CA—prostate cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—EP300—prostate cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.16e-06	1.82e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.16e-06	1.81e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PIK3CA—prostate cancer	2.15e-06	1.81e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—P4HB—prostate cancer	2.15e-06	1.81e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—MTHFR—prostate cancer	2.14e-06	1.8e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.14e-06	1.8e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CD—prostate cancer	2.12e-06	1.79e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—TYMS—prostate cancer	2.11e-06	1.78e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARA—prostate cancer	2.1e-06	1.77e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TGFB1—prostate cancer	2.1e-06	1.77e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GGT1—prostate cancer	2.09e-06	1.76e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTM1—prostate cancer	2.09e-06	1.76e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.09e-06	1.76e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GGT1—prostate cancer	2.07e-06	1.74e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—NOS3—prostate cancer	2.07e-06	1.74e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NCOA1—prostate cancer	2.06e-06	1.73e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—LPL—prostate cancer	2.05e-06	1.72e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NCOA1—prostate cancer	2.04e-06	1.72e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.03e-06	1.71e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.01e-06	1.69e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—NOS3—prostate cancer	2.01e-06	1.69e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MED12—prostate cancer	2e-06	1.68e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GNG5—prostate cancer	1.99e-06	1.67e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP1A1—prostate cancer	1.98e-06	1.67e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CAV1—prostate cancer	1.98e-06	1.66e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ERCC2—prostate cancer	1.96e-06	1.65e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTEN—prostate cancer	1.96e-06	1.65e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—RXRA—prostate cancer	1.96e-06	1.65e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—KRAS—prostate cancer	1.95e-06	1.64e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—RXRA—prostate cancer	1.94e-06	1.63e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOA3—prostate cancer	1.91e-06	1.61e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CB—prostate cancer	1.91e-06	1.61e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTGS2—prostate cancer	1.89e-06	1.59e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.89e-06	1.59e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—COMT—prostate cancer	1.89e-06	1.59e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTP1—prostate cancer	1.88e-06	1.58e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—EP300—prostate cancer	1.87e-06	1.57e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—COMT—prostate cancer	1.87e-06	1.57e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTP1—prostate cancer	1.86e-06	1.56e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CB—prostate cancer	1.85e-06	1.56e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ITPR1—prostate cancer	1.85e-06	1.55e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—MTHFR—prostate cancer	1.85e-06	1.55e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—AKT1—prostate cancer	1.84e-06	1.54e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTGS2—prostate cancer	1.83e-06	1.54e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ITPR1—prostate cancer	1.83e-06	1.54e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HPGDS—prostate cancer	1.83e-06	1.54e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.81e-06	1.53e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARA—prostate cancer	1.81e-06	1.52e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CG—prostate cancer	1.8e-06	1.51e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.8e-06	1.51e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CA—prostate cancer	1.79e-06	1.5e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—AKT1—prostate cancer	1.78e-06	1.5e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ACHE—prostate cancer	1.77e-06	1.49e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTT1—prostate cancer	1.77e-06	1.49e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—AKT1—prostate cancer	1.75e-06	1.48e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.75e-06	1.47e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—TYMS—prostate cancer	1.75e-06	1.47e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—TYMS—prostate cancer	1.73e-06	1.45e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TP53—prostate cancer	1.73e-06	1.45e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTM1—prostate cancer	1.73e-06	1.45e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTM1—prostate cancer	1.71e-06	1.44e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—INS—prostate cancer	1.71e-06	1.43e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CAV1—prostate cancer	1.7e-06	1.43e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.7e-06	1.43e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PRKACB—prostate cancer	1.69e-06	1.42e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—LPL—prostate cancer	1.69e-06	1.42e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—AKT1—prostate cancer	1.69e-06	1.42e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—LPL—prostate cancer	1.68e-06	1.41e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.68e-06	1.41e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CREBBP—prostate cancer	1.67e-06	1.4e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTEN—prostate cancer	1.65e-06	1.39e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.64e-06	1.38e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.63e-06	1.37e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ERCC2—prostate cancer	1.62e-06	1.36e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.62e-06	1.36e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CA—prostate cancer	1.61e-06	1.35e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ERCC2—prostate cancer	1.61e-06	1.35e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTEN—prostate cancer	1.6e-06	1.34e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOA2—prostate cancer	1.6e-06	1.34e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.58e-06	1.33e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—EP300—prostate cancer	1.57e-06	1.32e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CG—prostate cancer	1.55e-06	1.3e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—EP300—prostate cancer	1.53e-06	1.28e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—MTHFR—prostate cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—MTHFR—prostate cancer	1.51e-06	1.27e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARA—prostate cancer	1.5e-06	1.26e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NOS3—prostate cancer	1.5e-06	1.26e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.49e-06	1.25e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARA—prostate cancer	1.48e-06	1.25e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NQO1—prostate cancer	1.47e-06	1.24e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—INS—prostate cancer	1.47e-06	1.23e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—AKT1—prostate cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—TH—prostate cancer	1.45e-06	1.22e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CREBBP—prostate cancer	1.44e-06	1.21e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.41e-06	1.19e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CAV1—prostate cancer	1.41e-06	1.18e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CAV1—prostate cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CA—prostate cancer	1.38e-06	1.16e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.38e-06	1.16e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTGS2—prostate cancer	1.37e-06	1.15e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GGT1—prostate cancer	1.37e-06	1.15e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CD—prostate cancer	1.36e-06	1.15e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOA1—prostate cancer	1.35e-06	1.13e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.33e-06	1.12e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.33e-06	1.12e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—AKT1—prostate cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NOS3—prostate cancer	1.29e-06	1.08e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.28e-06	1.08e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—RXRA—prostate cancer	1.28e-06	1.08e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.27e-06	1.07e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—COMT—prostate cancer	1.23e-06	1.04e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTP1—prostate cancer	1.23e-06	1.03e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—INS—prostate cancer	1.21e-06	1.02e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ITPR1—prostate cancer	1.21e-06	1.02e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—INS—prostate cancer	1.2e-06	1.01e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTEN—prostate cancer	1.19e-06	1e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CB—prostate cancer	1.19e-06	1e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CREBBP—prostate cancer	1.19e-06	9.99e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTGS2—prostate cancer	1.18e-06	9.9e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CREBBP—prostate cancer	1.18e-06	9.9e-06	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CA—prostate cancer	1.16e-06	9.79e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—TYMS—prostate cancer	1.14e-06	9.59e-06	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—EP300—prostate cancer	1.14e-06	9.56e-06	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—AKT1—prostate cancer	1.13e-06	9.51e-06	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CA—prostate cancer	1.13e-06	9.49e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTM1—prostate cancer	1.13e-06	9.48e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.13e-06	9.47e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.12e-06	9.39e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LPL—prostate cancer	1.11e-06	9.31e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.07e-06	8.99e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NOS3—prostate cancer	1.06e-06	8.94e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ERCC2—prostate cancer	1.06e-06	8.92e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NOS3—prostate cancer	1.05e-06	8.86e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTEN—prostate cancer	1.03e-06	8.64e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTHFR—prostate cancer	9.97e-07	8.38e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CB—prostate cancer	9.82e-07	8.25e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—EP300—prostate cancer	9.8e-07	8.24e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARA—prostate cancer	9.78e-07	8.22e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CB—prostate cancer	9.73e-07	8.18e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTGS2—prostate cancer	9.73e-07	8.18e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTGS2—prostate cancer	9.64e-07	8.11e-06	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—AKT1—prostate cancer	9.51e-07	8e-06	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—AKT1—prostate cancer	9.22e-07	7.75e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CAV1—prostate cancer	9.19e-07	7.73e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTEN—prostate cancer	8.48e-07	7.13e-06	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CA—prostate cancer	8.41e-07	7.08e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTEN—prostate cancer	8.41e-07	7.07e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CG—prostate cancer	8.37e-07	7.04e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—EP300—prostate cancer	8.09e-07	6.8e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—EP300—prostate cancer	8.02e-07	6.74e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—INS—prostate cancer	7.93e-07	6.67e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CREBBP—prostate cancer	7.76e-07	6.53e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CD—prostate cancer	7.36e-07	6.19e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CA—prostate cancer	7.25e-07	6.09e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NOS3—prostate cancer	6.95e-07	5.85e-06	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—AKT1—prostate cancer	6.87e-07	5.78e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.42e-07	5.4e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTGS2—prostate cancer	6.36e-07	5.35e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CA—prostate cancer	5.98e-07	5.03e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CA—prostate cancer	5.93e-07	4.99e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—AKT1—prostate cancer	5.92e-07	4.98e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTEN—prostate cancer	5.55e-07	4.66e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—EP300—prostate cancer	5.29e-07	4.45e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—AKT1—prostate cancer	4.89e-07	4.11e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—AKT1—prostate cancer	4.85e-07	4.07e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.91e-07	3.29e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AKT1—prostate cancer	3.2e-07	2.69e-06	CbGpPWpGaD
